Inozyme Pharma Announces FDA Fast Track Designation For INZ-701, For The Treatment Of ABCC6 Deficiency
Portfolio Pulse from Benzinga Newsdesk
Inozyme Pharma (NASDAQ:INZY) has received FDA Fast Track designation for its drug INZ-701, aimed at treating ABCC6 Deficiency. This designation is expected to expedite the development and review process of the drug.
July 02, 2024 | 12:33 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Inozyme Pharma has received FDA Fast Track designation for its drug INZ-701, which is intended to treat ABCC6 Deficiency. This designation is likely to expedite the drug's development and review process, potentially bringing it to market faster.
The FDA Fast Track designation is a significant regulatory milestone that can expedite the development and review process of INZ-701. This increases the likelihood of the drug reaching the market sooner, which is positive news for Inozyme Pharma.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100